Retatrutide vs Tirzepatide

Dual agonist vs triple agonist: the current king vs the next frontier of weight loss.

Weight LossGLP-1MetabolicUpdated March 2026
VS

Quick Verdict

Tirzepatide is FDA-approved with proven 20–25% weight loss. Retatrutide adds a third receptor (glucagon) and shows up to 24% weight loss in Phase 2 — potentially the most powerful weight loss compound ever studied. Tirzepatide is the safer bet today; retatrutide is for those comfortable on the cutting edge.

Best for

Retatrutide

FDA-approved maximum weight loss, proven safety and efficacy data, dual-mechanism metabolic support.

Best for

Tirzepatide

Experimental maximum weight loss, treatment-resistant obesity, those who plateaued on tirzepatide, metabolic optimization via triple-receptor activation.

Head-to-Head Comparison

Retatrutide
Tirzepatide
Full Name
Retatrutide (Triple GIP/GLP-1/Glucagon Agonist)
Tirzepatide (Dual GIP/GLP-1 Agonist)
Category
Triple Incretin Agonist (GIP/GLP-1/Glucagon)
Dual GIP/GLP-1 Receptor Agonist
Mechanism
Activates all three incretin and glucagon receptors simultaneously — GIP, GLP-1, and glucagon. Provides enhanced metabolic effects beyond dual agonists through glucagon-mediated energy expenditure.
Dual agonist targeting both GIP and GLP-1 receptors. Provides enhanced insulin sensitivity, greater appetite suppression, and improved glucose metabolism compared to single-receptor agonists.
Best For
  • • Maximum weight loss (24%+ in trials)
  • • Treatment-resistant obesity
  • • Metabolic optimization
  • • Those who plateaued on semaglutide or tirzepatide
  • • Maximum weight loss (20–25% body weight)
  • • Type 2 diabetes management
  • • Superior appetite control
  • • Metabolic syndrome
Evidence Level
Moderate— Phase 2 trials showing up to 24% weight loss, Phase 3 ongoing
Strong— FDA-approved, SURMOUNT trials showing superior efficacy
Typical Dosing
Titrated up to 12mg weekly
Subcutaneous injection, once weekly
2.5mg–15mg weekly (titrated)
Subcutaneous injection, once weekly
Administration
Subcutaneous injection, once weekly
Subcutaneous injection, once weekly
Time to Effect
4–8 weeks for appetite; 12–24 weeks for significant weight loss
2–4 weeks for appetite; 12–20 weeks for significant weight loss
Side Effects
Nausea, diarrhea, vomiting, decreased appetite. Similar GI profile to other GLP-1s.
Nausea, diarrhea, decreased appetite (usually transient). Similar to semaglutide.
Blood Test
Required (A1c, metabolic panel, liver function)
Recommended (A1c, metabolic panel)
Price Tier
$$$$
$$$$
ProtocolRx
✓ We offer this
✓ We offer this

Which One Should You Choose?

Choose Retatrutide if you...

  • ✓Want the most aggressive weight loss option available
  • ✓Have treatment-resistant obesity
  • ✓Did not achieve goals with semaglutide or tirzepatide
  • ✓Want triple-mechanism metabolic support
  • ✓Are comfortable with a newer compound

Choose Tirzepatide if you...

  • ✓Want maximum possible weight loss
  • ✓Have type 2 diabetes or severe insulin resistance
  • ✓Did not get adequate results from semaglutide alone
  • ✓Want dual-mechanism metabolic support
  • ✓Are okay with weekly injections

Not sure which is right for you?

Take our quiz and we'll recommend the right compounds for your specific goals and health profile.

Build Your Protocol →

Related Comparisons

Semaglutide vs Tirzepatide→